ÕÒÂÛÎÄÍø > ҽҩѧÂÛÎÄ > ҩѧÂÛÎÄ >

X-Á¬ËøÎÞ±ûÖÖÇòµ°°×Ѫ֢µÄÑо¿½øÕ¹(1)

¡¾ÕªÒª¡¿  X-Á¬ËøÎÞ±ûÖÖÇòµ°°×Ѫ֢£¨X- linked agammaglobulinemia£¬XLA£©ÊôÓÚÔ­·¢ÐÔÌåÒºÃâÒßȱÏݲ¡ÖеÄÒ»ÖÖ£¬ÓÖ½ÐBruton²¡¡£½üÄêÀ´£¬ÓÉÓÚBrutonÀÒ°±Ëἤø£¨Bruton¡¯s agammaglobulinemia tyrosine kinase£¬BTK£©»ùÒòÍ»±äµ¼ÖÂBϸ°û·¢ÓýÕϰ­£¬ËùÒÔ²»ÄܲúÉúÃâÒßÇòµ°°×¡£±¾ÎľͽüÄêÀ´¶ÔBTKµÄÒÅ´«Ñ§ÌØÐÔ¡¢»ùÒòÍ»±ä·ÖÎö¡¢·Ö×ÓÖ²¡»úÖÆ¼°Õï¶ÏºÍÖÎÁƵȵÄÑо¿½øÕ¹×÷Ò»×ÛÊö¡£

    ¡¾¹Ø¼ü´Ê¡¿  X-Á¬ËøÎÞ±ûÖÖÇòµ°°×Ѫ֢£¨XLA£©£»BurtonÀÒ°±Ëἤø£¨BTK£©£»Õï¶Ï£»ÖÎÁÆ

    ¡¾Abstract¡¿  X-linked agammaglobulinemia£¨XLA £©belongs to the primary immunodeficiency disease£¨PID£©£¬which calls Bruton disease.Recently£¬it can not generate immune globulin£¬because of the mutation of the Bruton¡¯s agammaglobulinemia tyrosine kinase £¨BTK£© gene£¬which leads to developmental disorder of the B cell.This article reviews the genetic characters£¬mutation analysis£¬molecular pathogenic mechanism and therapy of the BKT gene.

    ¡¾Key words¡¿  XLA£»BTK£»diagnosis£»therapy

    XÁ¬ËøÎÞ±ûÖÖÇòµ°°×Ѫ֢£¨X-linked agammaglobulinemia£¬XLA£©£¬ÓÖ³ÆBrutonÎÞ±ûÖÖÇòµ°°×Ѫ֢£¬ÊÇ×îÔç·¢ÏÖµÄÈËÀàÔ­·¢ÐÔÃâÒßȱÏݲ¡£¨primary immunodeficiency disease£¬PID£©Ö®Ò»£¬Bruton£¨1952Ä꣩Ê״ᨵÀ¡£»¼ÕßÁÙ´²ÉÏÒÔ·´¸´Ï¸¾ú¸ÐÈ¾ÎªÌØÕ÷£¬ÑªÇåÖи÷ÀàÃâÒßÇòµ°°×Ã÷ÏÔ½µµÍ»òȱ·¦£¬¶Ô¿¹Ô­´Ì¼¤²»ÄܲúÉú¿¹ÌåÓ¦´ð£¬ÑªÑ­»·ÖÐBÁܰÍϸ°û¼õÉÙ£¬ÁܰͽἰÁܰÍ×é֯ȱ·¦Éú·¢ÖÐÐĺÍÁܰÍÂËÅÝ£¬¹ÇËèÖÐÎÞ½¬Ï¸°û£¬µ«Ç°BÁܰÍϸ°ûÊýÁ¿Õý³££¬TÁܰÍϸ°ûÊýÁ¿¼°¹¦ÄÜÕý³£¡£µäÐͲ¡ÀýΪ³öÉúºó°ëÄê×óÓÒ¿ªÊ¼·´¸´»¯Å§¸ÐȾ£¨Èç·ÎÑ×Á´Çò¾ú»òÊÈѪÁ÷¸Ð¸Ë¾ú£©»ò³ÙÖÁÓ×Äê·¢²¡£¬»¼ÕßÌåÄÚȱÉÙ³ÉÊìBϸ°û£¬»ù±¾Éϲ»ÄÜ×ÔÖ÷²úÉúÃâÒßÇòµ°°×£¬±ØÐëÒÀ¿¿ÃâÒßÌæ´úÁÆ·¨Î¬³ÖÌåÒºÃâÒßˮƽ¡£¸Ã²¡ÑÏÖØÎ£º¦»¼Õß½¡¿µ£¬Î£¼°»¼ÕßÉúÃü¡£80%¡«90%£Û1£ÝÁÙ´²Õï¶Ï²¡Àý¿É¼ì³öÏà¹ØÖ²¡»ùÒòBTK·¢ÉúÍ»±ä£¬¶øÆäËû10%¡«20%£Û1£ÝµÄ²¡ÈË´æÔÚÆäËûÎÊÌ⣬ÓÐÑо¿ÏÔʾ³£È¾É«Ìå±àÂëIg¦Õ£Û2£¬3£Ý¡¢¦ÌHC£Û4£ÝºÍLCµÄ»ùÒò´æÔÚÍ»±ä¡£

    1  BTKµÄÒÅ´«Ñ§ÌØÐÔ´ó¶àÊýPIDµÄÒÅ´«ÐÎʽÒѾ­Ã÷È·£¬¼¸ºõ¾ùΪµ¥»ùÒòÒÅ´«£¬¶àÊýΪ³£È¾É«ÌåÒþÐÔÒÅ´«£¬Æä´ÎΪXÁ¬ËøÒþÐԺͳ£È¾É«ÌåÏÔÐÔÒÅ´«¡£´ó¶àÊýÇé¿öÄÐÐÔ·¢²¡£¬Å®ÐÔЯ´ø£¬µ«Ò²ÓÐÄÐÐÔЯ´øÕß²»·¢²¡µÄ±¨µÀ¡£60%µÄPIDÍ»±ä»ùÒòµÄDNAÐòÁÐÒѱ»¿Ë¡£¬Í»±äλµã£¨°üÀ¨Í»±ä»ùÒò¶¨Î»µÄȾɫÌå½Ú¶ÎºÍ»ùÒòλµã£©ºÍÍ»±äÐÎʽ£¨µ¥¸öºËÜÕËáȱʧ¡¢Ìæ´ú¡¢²åÈë¡¢ÒÆÂëÍ»±ä¡¢ÎÞÒå»ò´íÒåÍ»±äµÈ£©Ò²ÒÑÈ·¶¨£Û5£Ý¡£ÔÚWHO PIDר¼ÒίԱ»áµÄÖ¸µ¼Ï£¬³ÉÁ¢ÁËÓйؼ²²¡»ùÒò¿â£¬¼Ç¼µÇ¼ÇÈ«Çò·¶Î§µÄPID»ùÒòÍ»±ä¼°ÆäÀàÐÍ¡£¶à»ùÒòÒÅ´«ÐÔPIDµÄÈ·¶¨½ÏÀ§ÄÑ£¬ÖÁ½ñÉÐÎÞÈ·Çеı¨µÀ¡£

    1.1  BTKµÄµ°°×½á¹¹  BTKµ°°×ΪBϸ°ûÐźŴ«µÝϵͳÖеÄÖØÒªµ°°×£¬ÊôÓÚ·ÇÊÜÌåÐ͵°°×ÀÒ°±ËἤøTec¼Ò×åµÄÒ»Ô±£¬¸Ã¼Ò×åµÄ³ÉÔ±»¹°üÀ¨TEC¡¢ITK/TSK/EMTºÍBMX¡£Tec¼Ò×åµ°°×ÀÒ°±Ëἤø°üÀ¨5¸ö²»Í¬µÄ½á¹¹Çø¶Î£¨¼ûͼ1£©£¬´ÓNÄ©¶ËÆðΪPH£¨pleckstrin homology£»PH£©¶Î£¬Ô¼ÓÐ120¸ö°±»ùËᣬTH£¨Tec homology£»TH£©¶ÎÔ¼ÓÐ60¡«80¸ö°±»ùËáSH3£¨Src homology3;SH3£©¶ÎÔ¼ÓÐ60¸ö°±»ùËᣬSH2¶ÎÔ¼100¸ö°±»ùËᣬ¼¤Ã¸´ß»¯¶ÎÔ¼280¸ö°±»ùËá£Û6£Ý¡£

    ͼ1  BTKµ°°×µÄ×é³É£¨´ÓN¶Ë¿ªÊ¼£©°üÀ¨5¸öÇøÓò£ºPH¡¢TH¡¢SH3¡¢SH2ºÍ¼¤Ã¸Çø¡£

    ×¢£ºÍ¼ÉϱߵÄÊý×Ö´ú±í¸÷¶ÎµÄ°±»ùË᳤¶È£¬Í¼Ï±ߵÄÊý×Ö´ú±í²»Í¬µÄÍâÏÔ×Ó¼°ÆäÏàÓ¦µÄλÖá£

    BTKµ°°×µÄ¿Õ¼ä½á¹¹¶àÊýÒѲâÃ÷£¬°üÀ¨PHÇø¡¢THÇøµÄǰ°ë²¿¡¢SH3ÇøºÍ¼¤Ã¸´ß»¯Çø£Û7£Ý£¬SH2ÇøµÄ½á¹¹¿É½èÓÃÆäËûµ°°×¼¤Ã¸µÄÀàËÆ½á¹¹½øÐÐÑо¿¡£ÕâЩÈýά¿Õ¼ä½á¹¹¿ÉÓÃÓÚ·ÖÎöÍ»±äÔì³ÉµÄµ°°×¿Õ¼ä½á¹¹µÄ¸Ä±ä¡£

    1.2  BTK»ùÒòµÄ·Ö×ӽṹ¼°ÆäÍ»±ä·ÖÎö  ÔÚ20ÊÀ¼Í80Äê´ú£¬¶àλѧÕßÓ¦ÓÃDNA¶à̬ÐÔ±êÖ¾·ÖÎöµÄ·½·¨£¬³É¹¦µØ½«XLAµÄȱÏÝ»ùÒò¶¨Î»ÓÚXȾɫÌåÖв¿£¨Xq21.3-22£©µÄ2cmÇøÓòÄÚ£Û8£Ý¡£VetrieµÈÓö¨Î»¿Ë¡·½·¨ÔÚXLA²¡±ä»ùÒòÇøÄÚ·ÖÀë¼ø¶¨ÁËÒ»¸öеĻùÒò£¬¸Ã»ùÒò±í´ïÓÚÕý³£È˸÷ÆÚBÁܰÍϸ°û£¬ÔÚXLA»¼ÕßÖз¢ÉúÍ»±ä£¬¹ÊÈÏΪÊÇXLAµÄÖ²¡»ùÒò¡£TsukadaµÈÒ²ÕÒµ½XLAµÄKDÖ²¡»ùÒò¡£BTK»ùÒòÈ«³¤37.5kb£¬º¬ÓÐ19¸öÍâÏÔ×Ó£¬³ýµÚÒ»ÍâÏÔ×ÓÍ⣬ÆäÓà18¸ö±àÂëBTKµ°°×µÄ659¸ö°±»ùËᣬ·Ö×ÓÁ¿Îª76KD£Û9£Ý¡£cDNAº¬ÓÐ2560¸öºËÜÕËᣬÓÐÒ»¸ö±àÂë659¸ö°±»ùËá¶àëĵĿª·ÅÔĶÁ¿ò¼Ü£¬ÆðʼÃÜÂë×ÓÔÚºËÜÕËáµÚ133λÖÃÉÏ£¬ÔÚÆðʼλÖÃÉÏÓεÄ15¸öÃÜÂë×Ó´¦ÔĶÁ¿ò¼Ü±ÕºÏ¡£¸ù¾Ý¹ú¼ÊÑо¿Ð¡×éBTKÍ»±ä·ÖÎö£¬Æù½ñÒѾ­ÔÚ471¸ö¼Ò×å544¸öXLA²¡ÈËÖз¢ÏÖÁËBTK»ùÒò341¸ö¶ÀÁ¢´æÔڵļî»ùÖû»¡¢²åÈë»òȱʧ£¬ÆäÖÐÓÐ13¸ö´ó¶ÎȱʧºÍ2¸ö´ó¶Î²åÈ롣ͻ±ä²»½ö´æÔÚÓÚ19¸öÍâÏÔ×Ó£¬»¹Éæ¼°ÄÚº¬×ÓºÍÆô¶¯ÇøÓò¡£ÆäÖУ¬·¢ÉúƵÂÊ×î¸ßµÄÊÇ´íÒåÍ»±ä£¬Æä´ÎÊÇÎÞÒåÍ»±äºÍÆ´½ÓλµãÍ»±ä¡£´íÒåÍ»±äÖ÷Òª·¢ÉúÔÚÈýÁªÌåÃÜÂë×ÓµÄǰÁ½Î»¡£ÍâÏÔ×Ó8ºÍ9µÄ185~287λûÓдíÒåÍ»±ä£¬ÕâЩλµã¿ÉÄܲ»Ò×Í»±ä»òÊǹ¦ÄÜÉϲ»ÖØÒª¡£33%µÄÌæ´úÀÛ¼°CPGË«ºËÜÕËᣬÕâÊÇĿǰÈÏΪµÄ×î³£¼ûµÄÍ»±äÈȵã£Û10£Ý£¬¶øÍ»±ä¸ßƵλµãR520Ò²ÊôÓÚCPGÍ»±ä£Û6£Ý¡£±àÂëÍâÏÔ×Óµ°°×Í»±äµÄÇøÓò£Û11£Ý£¨¼û±í1£©¡£±í1  ±àÂëÍâÏÔ×Óµ°°×Í»±äµÄÇøÓò

    2  BTKµÄ·Ö×ÓÖ²¡»úÖÆBTKÊôÓÚ·ÇÊÜÌåÀÒ°±Ëáµ°°×¼¤Ã¸£¬¸ÃÀ༤ø¹ã·º²ÎÓëϸ°ûÐźŴ«µ¼£¬Ó°Ïìϸ°ûµÄ´æ»î¡¢ÔöÖ³ºÍ·Ö»¯£¬BTKÊÇBϸ°û·¢Óý³ÉÊìµÄ¹Ø¼üÒòËØ¡£Õý³£È˳ýTϸ°ûºÍ½¬Ï¸°ûÍâ¾ùÓÐBTK±í´ï£¬¶øBTK»ùÒòÍ»±äÖ»Ó°ÏìBϸ°ûµÄÊýÁ¿£¬Õâ˵Ã÷BTKÔÚBϸ°ûµÄÉú³¤·¢Óý¹ý³ÌÖÐÆð×ÅÖÁ¹ØÖØÒªµÄ×÷Óá£Ä¿Ç°¶ÔBTK²ÎÓëϸ°ûÐźŴ«µ¼Ñо¿±È½ÏÇå³þµÄÊÇBCR½»Áª½éµ¼µÄÐźŴ«µ¼Í¾¾¶¡£Æä¹ý³Ì¼òÊöÈçÏ£ºBCR½»Áª¼¤»îPl-3¼¤Ã¸²¢²úÉúÒ»¶¨ÊýÁ¿µÄPl-3£¬4£¬5-risphosphateÓëĤ½áºÏ£¬Pl-3£¬4£¬5-risphosphateÓëBTKµÄSH3¶Î×÷ÓÃʹÆä¶¨Î»ÓÚϸ°ûĤ¡£È»ºó£¬BTK¾­¹ýÁ½²½»î»¯£ºÊ×ÏÈBTK¼¤Ã¸¶ÎY551λÁ×Ëữ£¨ºÜ¿ÉÄÜÊÇÓëLyn×÷Óã©£¬½Ó×ÅÊÇSH3¶ÎY223λµÄ×ÔÉíÁ×Ëữ¡£»î»¯ºóµÄBTKÓëBϸ°ûÏνӵ°°×£¨BLNK£©½áºÏ²¢¼¤»îphospholipase C -¦Ãy£¨PLC-¦Ã£©£¬µ¼Ö¸ÆÀë×ÓͨµÀ´ò¿ª£¬°ûÍâ¸ÆÀë×ÓÄÚÁ÷¡£¸ÃÐźŴ«µ¼Í¾¾¶×îÖÕµ¼ÖÂϸ°ûÔöÉú¼ÓÇ¿ºÍת¼µÄ±ä»¯¡£´Ëģʽ½öÏÞÓÚÒÔBϸ°ûÊÜÌå½»Áª×÷Ϊ´Ì¼¤Ðźţ¬ÖÁÓÚǰBϸ°ûÊÜÌå½»ÁªÊÇ·ñÒ²ÒýÆðÏàͬµÄÐźŴ«µ¼Ä¿Ç°»¹È±·¦Ö¤¾Ý£Û1£¬12£Ý¡£¸ÃÐźŴ«µ¼Í¾¾¶ÊÜFcR¢òBºÍSHIP£¨ SH2-containing inositol-5-phosphatase£©Á×Ëáø½éµ¼µÄÁíһ;¾¶ÖÆÔ¼£¬Í¨¹ýË®½âPl-3£¬4£¬5-risphosphateºÍIns£¨1£¬3£¬4£¬5£©-etraphosphate¹Ø±Õ¸ÆÀë×ÓÄÚÁ÷ͨµÀ£Û13£Ý¡£BTK²»½ö¿ÉÒÔÓÉBCRºÍFCR½éµ¼¼¤»î£¬Ò²¿ÉÒÔͨ¹ýÆäËûºÜ¶àÊÜÌ弤»î£¬°üÀ¨G-protein-coupled receptors£¨ GPCR£©¡¢IL-3¡¢IL-5ºÍIL-6£¬ÁíÍ⣬CD19ºÍµ¥¿Ë¡¿¹ÌåµÄ½»ÁªÒ²¿É¼¤»îBTK£Û13£Ý£¬½üÄêÀ´Ñо¿±íÃ÷£¬CD40Ò²ÊÇBϸ°û·¢Óý¹ý³ÌÖеÄÖØÒªÊÜÌ壬´«µÝ´Ì¼¤ÐźÅÓ°Ïìϸ°û´æ»î¡¢Éú³¤ºÍ·Ö»¯¡£ÓëBCR½éµ¼µÄBTK»î»¯Í¾¾¶ÏàËÆ£¬CD40µÄ½»ÁªÒ²¿É¼¤»îBTK¡£CD40ºÍBCR¿ÉÄÜÊÇBϸ°û·¢Óý¹ý³ÌÖв»Í¬½×¶Î¼¤»îBTKµÄÐźŴ«µÝͨ·¡£µ«Ò²ÓÐÑо¿ÌáʾCD40²»Í¨¹ýBTKÒ²¿ÉÌá¸ßNFKBºÍJNKµÄˮƽ£¬ÊǶÀÁ¢ÓÚBTKµÄÐźŴ«µ¼Í¨Â·£Û14¡«16£Ý¡£BTKÔÚϸ°ûÄÚÓëºÜ¶à·Ö×ÓÏ໥×÷Ó㬹²Í¬¹¹³ÉÁËÒ»ÖÖ΢»·¾³£¬ÔÚÐźŴ«µ¼µÄ¹ý³ÌÖÐÆð×ÅÖØÒªµÄ×÷Óá£ÕâЩ·Ö×Ó·Ö±ðÓëBTKµÄ²»Í¬Çø¶ÎÏ໥×÷Óã¬ÆäÖÐÓëPH¶Î×÷ÓõķÖ×ÓÑо¿µÃºÜ¶à£¬R28¸½½üÇøÓòÓëPIP3¡¢IP4¡¢PKC¦Â¢ñ¡¢BP-135¡¢F-ac-tin¡¢STAT3ºÍFas×÷Óá£PH- THÇøÓòÓëG¦ÁqºÍG¦ÂË«Ìå×÷ÓÃ;SH3Óëc-Cb1¡¢WASp¡¢VavºÍsab×÷ÓÃ;SH2ÓëÁ×ËữµÄBLNK×÷Óá£ÁíÍ⣬SH3ÓëTHÔÚBTK·Ö×ÓÄÚ×÷Óã¬ÒÖÖÆBTKµÄ»îÐÔ¡£ÔÚBCR½»Áª½éµ¼µÄÐźŴ«µ¼Í¾¾¶ÖУ¬SykºÍBLNK¶ÔBTKµÄ»î»¯ÆðÕýÏòµ÷½Ú×÷Óã¬Á×ËữµÄPKCs¡¢sabºÍIBTK¶ÔBTKµÄ»î»¯ÓÐÒÖÖÆ×÷Ó᣾¡¹ÜÓëBTK×÷ÓõķÖ×Ӻܶ࣬µ«ÊÇËüÃÇÈçºÎЭµ÷µØÓëBTK×÷Óã¬Íê³ÉBTK²ÎÓëµÄÐźŴ«µ¼£¬»úÖÆÄ¿Ç°Éв»Çå³þ£Û17£¬18£Ý¡£

¡¡¡¡3  XLAµÄÕï¶ÏXLAÊÇÒ»ÖÖÔ­·¢ÐÔÌåÒºÃâÒßȱÏÝÖ¢£¬Î£º¦×ÅÈËÃǵĽ¡¿µ¡£Òò¶ø£¬¶Ô¸ÃÖ¢½øÐвúǰÕï¶ÏºÍÅ®ÐÔЯ´øÕߵļø¶¨¾ÍÏÔµÃÊ®·ÖÖØÒª£Û19£Ý¡£ÎªÁËÑо¿XLA¼ÒϵŮÐÔ³ÉÔ±µÄÇé¿ö£¬FearonµÈ²ÉÓÃÁËXȾɫÌåʧ»îµÄ·½·¨È¥·¢ÏÖЯ´ø×´¿öÒÔ¼°ÑéÖ¤BÁܰÍϸ°û·¢ÓýµÄÄÚÔÚȱÏÝ¡£¸ù¾ÝÕâÒ»·½·¨ÓÃÖØ×éDNA̽Õëͬʱ·¢ÏÖRFLPºÍXȾɫÌå»ùÒò¼×»ù»¯¡£ÔÚÎÞЯ´ø×´Ì¬µÄÅ®ÐÔµÄÍâÖÜѪÁ£Ï¸°û¡¢TÁܰÍϸ°ûºÍBÁܰÍϸ°ûÖз¢ÏÖXȾɫÌåµÄËæ»úʧ»î¡£Ïà·´£¬¸ÃÖ¢µÄÈý¸öЯ´øÕßÔÚÍâÖÜBÁܰÍϸ°ûÁ½¸öXȾɫÌåÖеÄÒ»¸öÓÅÏÈʧ»î£¬µ«²»ÊÇTϸ°û»òÁ£Ï¸°û¡£ÕâÒ»·¢ÏÖÇ¿ÁÒµØÖ§³ÖXLAÊÇÓÉBÁܰÍϸ°û·¢ÓýµÄÄÚÔÚȱÏÝËùÖµļÙÉè¡£Lovering £¨1994£©µÈ£Û20£Ý¶ÔBTK»ùÒòȱʧ»¼ÕßDNA·Ö×Ó°ßµãÔÓ½»·ÖÎö¼ûµ½ÁËÒѸıäµÄDNAÏÞÖÆÐÔÆ¬¶Î£¬²¢¶Ô7¸ö»¼Õß¼ÒÍ¥ÓÃÒѾ­¸Ä±äµÄÏÞÖÆÐÔÆ¬¶Î·½·¨¶ÔÓ뻼ÕßÓйصÄÅ®ÐÔЯ´ø×´¿ö×÷³öÕï¶Ï¡£Ëæºó£¬SchusterµÈ£Û21£Ý±¨µÀÁ˶ÔËùÓÐ19¸öÍâÏÔ×Ó¡£°üÀ¨²àÒíÄÚº¬×ӱ߽ç²ÉÓÃPCR-SSCP·½·¨³É¹¦µØ¼ì²âµ½Á½ÀýÄÐÐÔ»¼¶ùBTKµÄSH2¹¦ÄÜÇøµÄÐÂÍ»±ä£¬²¢ÓÃÒ»¸öÒѸıä¹ýµÄµÚÒ»¸öÒýÎï×öPCRÀ©ÔöÍ»±ä·¢Éú£¬×÷³öÈý´úÖн¡¿µÅ®ÐÔЯ´øÕߵļø¶¨¡£½Ó×Å£¬HagemannµÈ£Û22£Ý¶ÔÒ»¸öÉ¢·¢µÄXLA»¼¶ù¼°¼ÒÍ¥µÄÈý´ú³ÉÔ±Ó¦ÓÃPCRÀ©Ôö»ùÒò×éDNA£¬²ÉÓÃÐòÁзÖÎöµÄ·½·¨Ö±½Ó¼ø¶¨XLAµÄ»ùÒòÍ»±ä£¬½á¹ûÕï¶Ï³ö»¼¶ù¼°ÆäÃâÒßѧ±íÏÖÕý³£µÄÅ®ÐÔЯ´øÕß¡£ÒÔÉÏÕâЩ·½·¨¾ù¿ÉÓ¦ÓÃÓÚ²úǰÕï¶Ï¡£ÕâÎÞÒɶÔÓÅÉúÓÅÓýÊǺÜÓÐÒâÒåµÄ¡£

¹²2Ò³: 1 [2] ÏÂÒ»Ò³


ÒȵºËØÖÎÁÆÖеÍѪÌÇÖ¢µÄÔ­Òò¼°»¤Àí
¸ßЧҺÏàÉ«Æ×·¨¼ì²âÈ¥Ñõ·úÄòÜÕ×¢ÉäÒºÓйØÎïÖÊ
¹¤É̹ÜÀí | ¹¤¿ÆÂÛÎÄ | ²ÆÎñ¹ÜÀí | ¹ÜÀíѧ | ¹«¹²¹ÜÀí | ²ÆÕþ˰ÊÕ | ֤ȯ½ðÈÚ | »á¼ÆÉó¼Æ | ¼ÆËã»ú | ·¨ÂÉÂÛÎÄ | ҽҩѧ | ººÓïÑÔÎÄѧ
Éç»áÂÛÎÄ | ¹¤¿ÆÂÛÎÄ | Àí¿ÆÂÛÎÄ | ÎÄ»¯ÂÛÎÄ | ÒÕÊõÂÛÎÄ | ÎÄѧÂÛÎÄ | ÕÜѧÂÛÎÄ | ÕþÖÎÂÛÎÄ | Ó¢ÓïÂÛÎÄ | д×÷Ö¸µ¼ | ¼ÆËã»úÓ¦ÓÃ
www.zlunwen.com ÕÒÂÛÎÄÍø ® °æÈ¨ËùÓÐ ÍøÕ¾µØÍ¼